Immune checkpoint blockade in renal cell carcinoma

Immune checkpoint blockade (ICB) is the foundation of current first‐line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long‐lasting remissions. With the expanding arsenal of ICB‐based therapies, biomarkers of response are urgently needed to guide...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of surgical oncology 2021-03, Vol.123 (3), p.739-750
Hauptverfasser:	Rappold, Phillip M., Silagy, Andrew W., Kotecha, Ritesh R., Hakimi, Ari A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - immunology Clinical Trials as Topic cytoreductive nephrectomy Humans Immune Checkpoint Inhibitors - immunology Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Kidney cancer Kidney Neoplasms - drug therapy Kidney Neoplasms - immunology Life Sciences & Biomedicine Oncology Randomized Controlled Trials as Topic Science & Technology Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Immune checkpoint blockade (ICB) is the foundation of current first‐line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long‐lasting remissions. With the expanding arsenal of ICB‐based therapies, biomarkers of response are urgently needed to guide optimal therapeutic selection. We review the data behind ICB therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in patients with mRCC.
ISSN:	0022-4790 1096-9098 1096-9098
DOI:	10.1002/jso.26339